SpecificationsOrganism/cell line/tissueHomo sapiens/dermal fibroblast cell lines expressing transforming factors from HGPS and age-matched control individualsSexMale and female cell linesSequencer or array typeIllumina HiSeq 2000Data formatFastqExperimental factorsHGPS vs. wild typeExperimental featuresChIP-seq, transcription factor binding sites, peak diffingConsentNASample source locationOriginal cell lines were obtained from Coriell Institute

Direct link to deposited data {#s0010}
=============================

Deposited data can be found at: <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE61325>.

Experimental design, materials and methods {#s0015}
==========================================

The overall aim was to identify specific and common genomic binding sites for BRD4 in experimentally transformed dermal fibroblasts derived from HGPS patients and control individuals through the analysis of BRD4 ChIP-sequencing data.

Cell culture {#s0020}
------------

Transformed cell lines were obtained by retroviral introduction of TERT (T), V12-HRAS (R) and SV40 large and small T antigens (S) of primary dermal fibroblasts from HGPS patients (TRS-HGPS) and age-matched control wild-type individuals (TRS-WT) as previously described [@bb0005], [@bb0010], [@bb0015]. Cells were grown in MEM containing 15% fetal bovine serum (FBS), 2 mM [l]{.smallcaps}-glutamine, 100 U ml^− 1^ penicillin and 100 μgml^− 1^ streptomycin, at 37 °C in 5% CO~2~. Two independent cell lines from each group were selected for ChIP-sequencing experiments.

ChIP-sequencing {#s0025}
---------------

ChIP was performed as previously described [@bb0020] with modifications. Briefly, 10 × 10^6^ cells were cross-linked for 10 min with formalin 1% at room temperature, followed by 5 minute quenching with 125 mM glycine. After three washes with chilled PBS, cell pellets were snap-frozen and stored at − 80 °C. Cells were resuspended in lysis buffer containing 1 mM EDTA, 0.8% SDS, 20 mM Tris--HCl pH 8 and protease inhibitor cocktail (Calbiochem) and sonicated in a Diagenode Bioruptor 300 for 12--15 cycles (30 s on, 60 s off). Chromatin was diluted in ChIP dilution buffer (1% Triton X-100, 1 mM EDTA, 20 mM Tris--HCl pH 8, 150 mM NaCl and protease inhibitor cocktail) and immunoprecipitated overnight with pre-coated anti-IgG magnetic beads (Dynabeads, Invitrogen) previously incubated with anti-BRD4 antibody (7 μg, Bethyl labs, lot A301-985) for 6 h at 4 °C. Beads were washed sequentially for 5 min each in low-salt (20 mM Tris--HCl pH 8, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100, 0.1% SDS), high-salt (20 mM Tris--HCl pH 8, 500 mM NaCl, 2 mM EDTA, 1% Triton X-100, 0.1% SDS), LiCl (10 mM Tris pH 8.0, 1 mM EDTA, 250 mM LiCl, 1% NP-40, 1% Na-deoxycholate) and TE (10 mM Tris--HCl pH 8, 1 mM EDTA) buffer at 4 °C followed by a room temperature wash in TE buffer. Beads were eluted in 1% SDS and 100 mM NaHCO~3~ buffer for 25 min at 65 °C and cross-linking was reversed for 8 h after addition of NaCl (final concentration 200 mM). After RNase A (1 mg/ml, Qiagen) and proteinase K (2 mg/ml, New England Biolabs) incubations, DNA was column-purified following the manufacturer\'s instructions (Qiaquick PCR purification kit, Qiagen).

Library construction (Illumina TruSeq 2.0 protocol) and sequencing were performed at the NCI-Sequencing Facility (SAIC-Frederick, MD) using Illumina HiSeq 2000. Paired-end sequencing with read lengths of 100 bp was performed. 4 input samples and 4 BRD4-ChIP samples (from TRS-WT and TRS-HGPS cells, two independent cell lines in each group) were multiplexed in two lanes. Raw reads files in fastq format were deposited to the SRA database at NCBI ([Table 1](#t0005){ref-type="table"}).

ChIP-seq data analysis {#s0030}
----------------------

The data analysis procedure is described in [Fig. 1](#f0005){ref-type="fig"}. The raw reads data quality was tested using FastQC [@bb0025] (V0.10.1). All samples showed all base quality ≥ 25 and a small number of TruSeq adapter sequences was detected in the WT1 BRD4 reads. Raw reads of each sample in fastq format were then aligned to reference human genome (hg19) using NovoalignMPI (V3.0.2, Novocraft) and the adapter sequence contamination in WT1 BRD4 sample was removed during mapping using "-a" option in command line. In addition, the program was instructed to only report the uniquely aligned reads by skipping the "-r" option. The mapping results in BAM format were preprocessed using Picard tools [@bb0030] (V1.119) to reorder, sort reads and the duplicated reads were removed as well. The clean bam files were in turn converted to bed format using "bamToBed" script in bedtools [@bb0035] (V2.19) in order to be analyzed using SICER [@bb0040] (V1.1). Given the reported binding nature of BRD4 [@bb0045], 200 bp window size and 400 bp gap size were chosen in the peak calling step using SICER. Statistically significant peaks were detected using 1% FDR as the cutoff. Peak numbers from each sample are shown in [Table 2](#t0010){ref-type="table"}.

Peak signals were visualized using Integrative Genomics Viewer (IGV) [@bb0050] for basic quality check; in addition, DiffBind [@bb0055] was applied to the peak data to examine the correlation of WT and HGPS samples using all default settings. In order to investigate potential differences in BRD4 binding patterns in WT and HGPS samples, a pipeline was developed to detect sample-specific BRD4 bindings. First, the union of the peaks in each biological group was calculated using the "find_union_islands.py" script in SICER, and then the intersection of peaks in each group was achieved using the "intersect" command in bedtools, and finally, the sample-specific peaks were derived by comparing the union peak sets with the intersected peak sets from different samples using "-v" option in the "intersect" command. In this way, 3078 WT-specific and 5574 HGPS-specific BRD4 binding sites were detected and the annotation of the peaks was done using "annotatePeaks.pl" with default options in Homer [@bb0060]. Important genomic features e.g., promoter, 5′/3′ UTR, exon, intron, non-coding were used to annotate the peaks and differential enrichment in specific features were compared between wild type and HGPS samples, as interpreted in [@bb0005]. Common BRD4 binding sites were detected by "multiinter" command in bedtools and annotated using Homer. All annotated specific and common genomic binding sites between WT and HGPS cell lines are provided in [Table 3](#ec0005){ref-type="supplementary-material"}, [Table 4](#ec0010){ref-type="supplementary-material"}, [Table 5](#ec0015){ref-type="supplementary-material"}.

The following are the supplementary data related to this article.Table 3WT-specific sites.Table 4HGPS-specific sites.Table 5WT and HGPS common sites.
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###### 

Sample names and their corresponding raw read file names in NCBI SRA archive database.

  File names   Sample names   Group
  ------------ -------------- ----------------
  SRR1574701   HG1 Input      TRS-HGPS cells
  SRR1574702   HG2 Input      TRS-HGPS cells
  SRR1574697   HG1 BRD4       TRS-HGPS cells
  SRR1574698   HG2 BRD4       TRS-HGPS cells
  SRR1574699   WT1 Input      TRS-WT cells
  SRR1574700   WT2 Input      TRS-WT cells
  SRR1574695   WT1 BRD4       TRS-WT cells
  SRR1574696   WT2 BRD4       TRS-WT cells

###### 

Number of peaks from each sample detected by SICER.

  Samples   WT1     WT2     HG1     HG2
  --------- ------- ------- ------- -------
  Peaks     29990   32239   35292   42784
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